CoChat

A Randomized, Double-Blind, Placebo-Controlled Trial of Pleconaril for the Treatment of Neonates With Enterovirus Sepsis

Open access
Abzug, Mark J., Michaels, Marian G., Wald, Ellen, Jacobs, Richard F., Romero, José R., Sánchez, Pablo J., Wilson, Gregory, Krogstad, Paul, Storch, Gregory A., Lawrence, Robert, Shelton, Mark, Palmer, April, Robinson, Joan, Dennehy, Penelope, Sood, Sunil K., Cloud, Gretchen, Jester, Penelope, Acosta, Edward P., Whitley, Richard, Kimberlin, David · 2016 · Journal of the Pediatric Infectious Diseases Society
Cited by 155

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Neonatal enterovirus sepsis has high mortality. Antiviral therapy is not available. METHODS: Neonates with suspected enterovirus sepsis (hepatitis, coagulopathy, and/or myocarditis) with onset at ≤15 days of life were randomized 2:1 to receive oral pleconaril or placebo for 7 days. Serial virologic (oropharynx, rectum, urine, serum), clinical, pharmacokinetic, and safety evaluations were performed. RESULTS: Sixty-one subjects were enrolled (43 treatment, 18 placebo), of whom 43 were confirmed enterovirus infected (31 treatment, 12 placebo). There was no difference in day 5 oropharyngeal culture positivity (primary endpoint; 0% in both groups). However, enterovirus-infected subjects in the treatment group became culture negative from all anatomic sites combined faster than placebo group subjects (median 4.0 versus 7.0 days, P = .08), and fewer subjects in the treatment group remained polymerase chain reaction (PCR)-positive from the oropharynx when last sampled (23% versus 58%, P = .02; median, 14.0 days). By intent to treat, 10/43 (23%) subjects in the treatment group and 8/18 (44%) in the placebo group died (P = .02 for 2-month survival difference); among enterovirus-confirmed subjects, 7/31 (23%) in the treatment group died versus 5/12 (42%) in the placebo group (P = .26). All pleconaril recipients attained concentrations greater than the IC90 after the first study day, but 38% were less than the IC90 during the first day of treatment. One subject in the treatment group and three in the placebo group had treatment-related adverse events. CONCLUSIONS: Shorter times to culture and PCR negativity and greater survival among pleconaril recipients support potential efficacy and warrant further evaluation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/jpids/piv015

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 155

Metadata

Authors
Abzug, M. J., Michaels, M. G., Wald, E., Jacobs, R. F., Romero, J. R., Sánchez, P. J., Wilson, G., Krogstad, P., Storch, G. A., Lawrence, R., Shelton, M., Palmer, A., Robinson, J., Dennehy, P., Sood, S. K., Cloud, G., Jester, P., Acosta, E. P., Whitley, R., & Kimberlin, D.
Venue
Journal of the Pediatric Infectious Diseases Society
Published
2015-04-16
Volume
5
Issue
1
Pages
53-62
ISSN
  • 2048-7193 (ISSN-L)
  • 2048-7207
OpenAlex
W2117951318
Cited by
155
References
2
FWCI
9.59
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Randomized, Double-Blind, Placebo-Controlled Trial of Pleconaril for the Treatment of Neonates With Enterovirus Sepsis. https://app.cochat.ai/papers/10.1093/jpids/piv015
The paper
Abzug, M. J., Michaels, M. G., Wald, E., Jacobs, R. F., Romero, J. R., Sánchez, P. J., Wilson, G., Krogstad, P., Storch, G. A., Lawrence, R., Shelton, M., Palmer, A., Robinson, J., Dennehy, P., Sood, S. K., Cloud, G., Jester, P., Acosta, E. P., Whitley, R., & Kimberlin, D. (2016). A Randomized, Double-Blind, Placebo-Controlled Trial of Pleconaril for the Treatment of Neonates With Enterovirus Sepsis. Journal of the Pediatric Infectious Diseases Society. https://doi.org/10.1093/jpids/piv015

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.